Kerr B, Delrue M-A, Sigaudy S, Perveen R, Marche M, Burgelin I, Stef M, Tang B, Eden O B, O'Sullivan J, De Sandre-Giovannoli A, Reardon W, Brewer C, Bennett C, Quarell O, M'Cann E, Donnai D, Stewart F, Hennekam R, Cavé H, Verloes A, Philip N, Lacombe D, Levy N, Arveiler B, Black G
Regional Genetic Service, Central Manchester University Hospital NHS Trust, Manchester, UK.
J Med Genet. 2006 May;43(5):401-5. doi: 10.1136/jmg.2005.040352. Epub 2006 Jan 27.
Costello syndrome (CS) is a rare multiple congenital abnormality syndrome, associated with failure to thrive and developmental delay. One of the more distinctive features in childhood is the development of facial warts, often nasolabial and in other moist body surfaces. Individuals with CS have an increased risk of malignancy, suggested to be about 17%. Recently, mutations in the HRAS gene on chromosome 11p13.3 have been found to cause CS.
We report here the results of HRAS analysis in 43 individuals with a clinical diagnosis of CS.
Mutations were found in 37 (86%) of patients. Analysis of parental DNA samples was possible in 16 cases for both parents and in three cases for one parent, and confirmed the mutations as de novo in all of these cases. Three novel mutations (G12C, G12E, and K117R) were found in five cases.
These results confirm that CS is caused, in most cases, by heterozygous missense mutations in the proto-oncogene HRAS. Analysis of the major phenotypic features by mutation suggests a potential correlation between malignancy risk and genotype, which is highest for patients with an uncommon (G12A) substitution. These results confirm that mutation testing for HRAS is a reliable diagnostic test for CS.
科斯特洛综合征(CS)是一种罕见的多发性先天性异常综合征,与生长发育迟缓有关。儿童期较为独特的特征之一是面部疣的出现,常见于鼻唇沟及其他身体潮湿部位。CS患者患恶性肿瘤的风险增加,据推测约为17%。最近发现,位于11号染色体p13.3上的HRAS基因突变会导致CS。
我们在此报告对43例临床诊断为CS的个体进行HRAS分析的结果。
37例(86%)患者发现有突变。16例可对父母双方的DNA样本进行分析,3例可对一方父母的样本进行分析,所有这些病例均证实突变为新发突变。5例患者发现了3种新突变(G12C、G12E和K117R)。
这些结果证实,在大多数情况下,CS是由原癌基因HRAS的杂合错义突变引起的。通过突变分析主要表型特征表明,恶性肿瘤风险与基因型之间可能存在相关性,对于具有罕见(G12A)替代的患者,这种相关性最高。这些结果证实,HRAS突变检测是CS的可靠诊断方法。